v3.26.1
Segment Reporting - Summary of Disaggregated Amounts Research and Development Expenses and Segment Net Loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting Information [Line Items]            
Primary program research and development expenses [1] $ 15,919   $ 16,708   $ 31,907 $ 31,447
Total other research and development expenses 3,950   3,658   7,820 7,172
Research and development operating costs and expenses excluding non-cash stock-based compensation 19,869   20,366   39,727 38,619
General and administrative expense excluding non-cash stock-based compensation 13,303   8,371   21,684 15,551
Other segment income (expense), net [2] 7,056   1,664   16,101 2,870
Net loss (40,228) $ (37,284) (30,401) $ (26,639) (77,512) (57,040)
Payroll and Benefits [Member]            
Segment Reporting Information [Line Items]            
Total other research and development expenses 3,384   3,210   6,619 6,098
Occupancy and Other Overhead and Operating Costs [Member]            
Segment Reporting Information [Line Items]            
Total other research and development expenses $ 566   $ 448   $ 1,201 $ 1,074
[1] Primary program research and development expenses are comprised primarily of costs paid to third parties for clinical trials and product development manufacturing, nonclinical, regulatory, and quality assurance activities, and the portion of related research and development expenses incurred by our collaborators and third-party service providers, including contract research and manufacturing organizations that we are obligated to reimburse.
[2] Other segment income (expense), net includes interest income, interest expense, foreign currency exchange gain or loss, depreciation and amortization, non-cash stock-based compensation, loss on extinguishment of debt (for the six months ended June 30, 2025), and tax credit income.